r.rotation.to⌕ Search stocks, people, sectors
Request a free account

Follow the people · Insider

RP

RA CAPITAL MANAGEMENT, L.P.

Insider · Director and 10% owner · ARTV

RA CAPITAL MANAGEMENT, L.P. files insider transactions with the SEC as a director and 10% owner of Artiva Biotherapeutics (ARTV). We hold 69 disclosed purchases and sales filed since 13 June 2008, 34 of them in the last 90 days.

  • Files forARTV
  • Disclosed buys and sells69 in all, 34 in the last 90 days
  • Last disclosure26 August 2026

Positions held

20 posts we hold — a term names its own dates; a run of filings only says when they filed
  • Filed 24 June 2025 — 8 September 2026Director and 10% owner · Artiva Biotherapeutics (ARTV)23 Form 4 lines · source: SEC Form 4
  • Filed 9 February 2021 — 24 August 202610% owner · Vor Biopharma (VOR)40 Form 4 lines · source: SEC Form 4
  • Filed 26 June 2026 — 12 August 2026Director and 10% owner · Septerna (SEPN)3 Form 4 lines · source: SEC Form 4
  • Filed 29 July 2026 — 29 July 202610% owner · Inhibikase Therapeutics (IKT)2 Form 4 lines · source: SEC Form 4
  • Filed 9 June 2026 — 22 July 2026Director and 10% owner · Parabilis Medicines (PBLS)15 Form 4 lines · source: SEC Form 4
  • Filed 20 July 2026 — 20 July 2026Director and 10% owner · Freenome (FRNM)7 Form 4 lines · source: SEC Form 4
  • Filed 5 January 2026 — 29 June 2026Director and 10% owner · Climb Bio (CLYM)4 Form 4 lines · source: SEC Form 4
  • Filed 29 August 2023 — 24 June 2026Director and 10% owner · ARS Pharmaceuticals (SPRY)5 Form 4 lines · source: SEC Form 4
  • Filed 18 June 2026 — 18 June 2026Director and 10% owner · PepGen (PEPG)1 Form 4 line · source: SEC Form 4
  • Filed 24 May 2024 — 17 June 202610% owner · Werewolf Therapeutics (HOWL)21 Form 4 lines · source: SEC Form 4
  • Filed 13 June 2025 — 17 June 2026Director and 10% owner · Acrivon Therapeutics (ACRV)4 Form 4 lines · source: SEC Form 4
  • Filed 10 February 2025 — 17 June 2026Director and 10% owner · Sionna Therapeutics (SION)41 Form 4 lines · source: SEC Form 4
  • Filed 4 May 2026 — 16 June 202610% owner · Hemab Therapeutics Holdings (COAG)25 Form 4 lines · source: SEC Form 4
  • Filed 15 June 2026 — 15 June 2026Director and 10% owner · LENZ Therapeutics (LENZ)1 Form 4 line · source: SEC Form 4
  • Filed 15 June 2021 — 11 June 2026Director and 10% owner · Janux Therapeutics (JANX)14 Form 4 lines · source: SEC Form 4
  • Filed 27 March 2024 — 10 June 2026Director and 10% owner · Nkarta (NKTX)4 Form 4 lines · source: SEC Form 4
  • Filed 12 September 2024 — 9 June 2026Director and 10% owner · Bicara Therapeutics (BCAX)6 Form 4 lines · source: SEC Form 4
  • Filed 21 July 2023 — 3 June 2026Director and 10% owner · Acumen Pharmaceuticals (ABOS)4 Form 4 lines · source: SEC Form 4
  • Filed 13 June 2022 — 28 May 2026Director and 10% owner · Tyra Biosciences (TYRA)6 Form 4 lines · source: SEC Form 4
  • Filed 27 April 2026 — 27 April 202610% owner · Prelude Therapeutics (PRLD)2 Form 4 lines · source: SEC Form 4

Everything they disclosed

120 entries, newest first — one per disclosure report, one per Form 4 line

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.